Tier 2 — strong
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
European review for medical and pharmacological sciences
2023
27(14):6718-6727
Bibliography
- PubMed
- PMID 37522683
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Randomized double-blind placebo-controlled formulation trial |
|---|---|
| Model | Human participants; see population |
| Sample | 49 overweight adults with impaired fasting glucose |
| Intervention | Berberine Phytosome: two 550-mg formulation tablets/day versus placebo |
| Duration | 60 days |
| Endpoints | Fasting and postload glucose; HbA1c and insulin sensitivity; Lipid profile and tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Best Berberine Supplements: Formulas, Testing and Value ComparedCompare the best berberine supplement options using official labels, testing claims, active amounts, current price context, safety and clear buying criteria.Read analysis
- Berberine Phytosome vs Liposomal Berberine: Absorption ExplainedCompare berberine Phytosome, liposomal and micellar delivery. Understand active doses, absorption studies, clinical outcomes, tolerability and value.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
